Skip to main content

Breakthroughs in Drug development

World’s fastest AI-discovered medicine enters phase 2a trial, marking breakthroughs in drug development


Researchers from Peking Union Medical College Hospital and artificial intelligence (AI) drug developer Insilico Medicine published phase 2a clinical trial data for a small-molecule treatment for idiopathic pulmonary fibrosis (IPF) in Nature Medicine magazine on Tuesday. Data demonstrates preliminary safety and efficacy of the drug candidate, making it the fastest-progressing AI-discovered drug worldwide to date, according to a report by The Paper.

IPF is a chronic, progressive lung disease characterized by irreversible decline in lung function, affecting an estimated 5 million people worldwide. The median survival is only three to four years. Existing treatments can slow the disease's progression but cannot halt or reverse it, according to The Paper. The molecule tested in this trial, Rentosertib, targets TNIK - a novel site identified with the help of AI, as research group say in the Nature Medicine.

In the development of new drugs, a "target" is like a lock that a drug - the key- must fit. Traditionally, identifying the correct target is time-consuming and depends heavily on trials and errors. In the case of Rentosertib, AI helped researchers pinpoint a previously overlooked target, significantly enhancing discovery efficiency, Chen Jing, a vice president of the Technology and Strategy Research Institute, told the Global Times on Wednesday.

"AI has already made major breakthroughs in drug-related fields," Chen said. "Its success in identifying a novel target represents a natural extension of that capability into basic research. The core competency is present - with ongoing data accumulation and training, large-scale application and major results are only a matter of time."

While AI has long been expected to accelerate drug development by efficiently screening compounds, simulating mechanisms and supporting clinical trial design, no AI-discovered drugs had advanced beyond phase 1 trials until now. Rentosertib's progression into phase 2a marks a significant milestone, demonstrating AI's tangible impact on real-world pharmaceutical innovation, per the report.

Clinical observations showed that Rentosertib had demonstrated manageable safety and tolerability, laying the groundwork for larger and longer-term trials. The experience with Rentosertib highlights the transformative potential of AI in drug development and offers a valuable reference for more efficient and innovative approaches, said Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine, the report noted.

"AI is making steady progress in fields such as medical imaging, clinical decision support, and personalized health monitoring," Chen said. "But in drug development, it still faces major challenges — from limited access to high-quality data and poor model interpretability to high computational costs and a shortage of interdisciplinary talent. Intellectual property and regulatory frameworks also need to evolve. If these issues are properly addressed, AI has the potential to truly advance inclusive and accessible healthcare forward."

AI applications in China's healthcare sector are expected to expand in scale and diversify across more use cases in the future, expert said. China's medical AI market is projected to reach $13.4 billion by 2026, with an annual growth rate exceeding 40 percent, according to an IDC report, quoted by the Xinhua News Agency.

Comments

Post a Comment

Popular posts from this blog

Genetics role in ovarian cancer

The Medical Minute: Genetics play big role in ovarian cancer In 2024, about 19,680 women in the United States will receive a new diagnosis of ovarian cancer and 12,740 women will die from the disease, said Dr. Shaina Bruce , a gynecologic oncologist at Penn State Cancer Institute . The median age of all patients who develop ovarian cancer is 63. Historically, women at increased risk for ovarian cancer are recommended to have their fallopian tubes and ovaries removed when they have completed having children. Taking that step to protect themselves comes at a heavy price ― surgical menopause. But Bruce said medical science is catching up with ovarian cancer. Studies could lead to new methods for preventative care and the surgery needed to lower risk may be easier than it once was. Below, during Gynecologic Cancer Awareness Month, Bruce discusses the disease and why acting to reduce your risk is worth it. What’s the connection between heredity and ovarian cancer? About 25% of all cases of ...
Post a Comment
Read more

Migration in Population Genetics

  Migration in Population Genetics Migration in population genetics refers to the movement of individuals-and therefore their genes -between different populations of the same species. This gene flow alters allele frequencies, increasing genetic diversity within populations while reducing genetic differences between them. Migration can counteract the effects of genetic drift and inbreeding , introduce new alleles , and influence evolutionary processes such as adaptation and natural selection. The rate, direction, and scale of migration play a crucial role in shaping population structure, evolutionary potential, and long-term species survival, especially in fragmented habitats or changing environments. Migration, Population Genetics, Gene Flow, Allele Frequency, Genetic Diversity, Evolution, Genetic Variation, Population Structure, Adaptation, Biodiversity #PopulationGenetics #Migration #GeneFlow #GeneticDiversity #EvolutionaryBiology #AlleleFrequency #NaturalSelection #GeneticD...
Post a Comment
Read more

Chromosomal Abnormalities

  Chromosomal Abnormalities Chromosome abnormalities refer to structural or numerical changes in chromosomes that can disrupt normal genetic function, leading to developmental disorders, congenital abnormalities, and various genetic diseases. These abnormalities may arise from errors in cell division, such as nondisjunction or chromosomal breakage, resulting in conditions like Down syndrome , Turner syndrome, Klinefelter syndrome , and various deletion or duplication syndromes. Understanding chromosome abnormalities is essential for genetic counseling, prenatal diagnosis, disease risk assessment, and research in cytogenetics and molecular genetics. Chromosome abnormalities, chromosomal disorders, chromosomal mutations, aneuploidy, structural chromosome abnormalities, nondisjunction, deletion syndrome, duplication syndrome , translocation, inversion, cytogenetics, karyotyping, prenatal diagnosis , genetic testing, genomic instability, Down syndrome, Turner syndrome, Klinefelter syn...
Post a Comment
Read more